Compare Biogen Inc (BIIB) vs Hasbro, Inc. (HAS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Hasbro, Inc. — how do they compare? Biogen Inc trades at $192.49 (market cap $28.34B), while Hasbro, Inc. trades at $79.25 (market cap $11.10B). The key difference: Biogen Inc is far larger — about 2.6× Hasbro, Inc.'s market cap, and Hasbro, Inc. pays a 3.57% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | HAS | |
|---|---|---|
Market Cap | $28.34B | $11.10B |
Sector | Health | Consumer Cyclical |
52-Week High | $216.63 | $105.88 |
52-Week Low | $122.68 | $70.95 |
Enterprise Value | $30.62B | $13.37B |
Dividend Yield | — | 3.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Hasbro (HAS) trades at $79.53, showing modest daily gains but facing bearish technical signals. The company reported negative net income of -$322.4M in 2025 despite revenue growth to $4.7B, with profitability metrics showing strain. Recent earnings beats provide some optimism, while analyst consensus remains positive with a $104 price target representing 31% upside potential from current levels.
Investment outlook balances strong analyst support against fundamental challenges. The stock offers significant upside if management can improve profitability, but faces headwinds from negative margins and high debt levels. Key catalysts include Q2 2026 earnings on July 21 and execution of the company's 'aging up' strategy targeting adult consumers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →
